During the last session, Jasper Therapeutics Inc (NASDAQ:JSPR)’s traded shares were 0.38 million, with the beta value of the company hitting 2.05. At the end of the trading day, the stock’s price was $5.70, reflecting an intraday loss of -2.90% or -$0.17. The 52-week high for the JSPR share is $31.01, that puts it down -444.04 from that peak though still a striking 7.89% gain since the share price plummeted to a 52-week low of $5.25. The company’s market capitalization is $85.51M, and the average intraday trading volume over the past 10 days was 1.53 million shares, and the average trade volume was 448.54K shares over the past three months.
Jasper Therapeutics Inc (JSPR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. JSPR has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.26.
Jasper Therapeutics Inc (NASDAQ:JSPR) trade information
Jasper Therapeutics Inc (JSPR) registered a -2.90% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.90% in intraday trading to $5.70, hitting a weekly high. The stock’s 5-day price performance is 6.74%, and it has moved by -73.57% in 30 days. Based on these gigs, the overall price performance for the year is -47.85%. The short interest in Jasper Therapeutics Inc (NASDAQ:JSPR) is 2.32 million shares and it means that shorts have 11.87 day(s) to cover.
The consensus price target of analysts on Wall Street is $55.5, which implies an increase of 89.73% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $48 and $63 respectively. As a result, JSPR is trading at a discount of -1005.26% off the target high and -742.11% off the low.
Jasper Therapeutics Inc (JSPR) estimates and forecasts
Statistics show that Jasper Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Jasper Therapeutics Inc (JSPR) shares have gone down -72.53% during the last six months, with a year-to-date growth rate more than the industry average at 27.51% against 16.50.
While earnings are projected to return 26.45% in 2025, the next five years will return 6.78% per annum.
JSPR Dividends
Jasper Therapeutics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Jasper Therapeutics Inc (NASDAQ:JSPR)’s Major holders
Jasper Therapeutics Inc insiders own 1.28% of total outstanding shares while institutional holders control 98.99%, with the float percentage being 100.27%.
Also, the Mutual Funds coming in first place with the largest holdings of Jasper Therapeutics Inc (JSPR) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 401.22 shares. This amounts to just over 2.67 percent of the company’s overall shares, with a $2.29 million market value. The same data shows that the other fund manager holds slightly less at 296.68, or about 1.98% of the stock, which is worth about $1.69 million.
